180200-68-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluoro-benzenesulfonamide is used as a pharmaceutical compound for its potential therapeutic applications. The unique structural features of this molecule allow it to interact with various biological targets, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, 4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluoro-benzenesulfonamide can be utilized as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique structure and functional groups make it a valuable tool for exploring new chemical reactions and developing novel compounds with specific properties.
Used in Material Science:
The compound may also find applications in material science, where its unique structural features could be exploited to create new materials with tailored properties. For example, it could be used in the development of advanced polymers, coatings, or other materials with specific characteristics, such as improved stability, enhanced mechanical properties, or unique optical or electronic properties.

InChI:InChI=1/C16H19FN2O3S/c1-10-19-15(11-5-3-2-4-6-11)16(22-10)12-7-8-14(13(17)9-12)23(18,20)21/h7-9,11H,2-6H2,1H3,(H2,18,20,21)

Upstream product

• 180200-78-6 4-cyclohexyl-5-(3-fluorophenyl)-2-methyloxazole 
• 180200-79-7 5-(4-chlorosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole 

Downstream Products

• 415679-04-8 2-benzylamino-4-(4-cyclohexyl-2-methyl-oxazol-5-yl)-benzenesulfonamide 
• 415679-00-4 2-benzyloxy-4-(4-cyclohexyl-2-methyloxazol-5-yl)benzenesulfonamide 
• 415679-01-5 4-(4-cyclohexyl-2-methyl-oxazol-5-yl)-2-hydroxy-benzenesulfonamide 

Relevant academic research and scientific papers

Agents and methods for treatment of cancer

Agents and methods for chemoprevention and treatment of neoplasia are described, the agents including a selective inhibitor of inducible nitric oxide synthase and a combination of a selective inhibitor of inducible nitric oxide synthase and an inhibitor of cylcooxygenase-2 in a pharmaceutical composition. The agents and methods are used for chemoprevention and treatment of neoplasia including colorectal cancer and other cancers affecting epithelial cells throughout the body. The agents can also be used to treat the fibrosis that occurs with radiation therapy, as well as adenomatous polyps, including those with familial adenomatous polyposis (FAP).

Method for the treatment and prevention of cachexia

Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.

Antiangiogenic combination therapy for the treatment of cancer

The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.

4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: Enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522

A series of 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamide derivatives were synthesized and evaluated for their abilities to inhibit cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1) enzymes. In this series, substituent effects at the ortho position to the sulfonamide group on the phenyl ring were examined. Most substituents reduced or lost both COX-2 and COX-1 activities. In contrast, introduction of a fluorine atom preserved COX-2 potency and notably increased COX1/COX-2 selectivity. This work led to the identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522 [9d, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide], which is currently in phase II clinical trials for the treatment of rheumatoid arthritis, osteoarthritis, and acute pain.

Process for producing oxazole compound

The present invention relates to a method for producing a compound of the formula [7] wherein R1is an optionally substituted cycloalkyl group, an optionally substituted aryl group or an optionally substituted heterocyclic group, R2is a lower alkyl or a halogenated lower alkyl and R3is a halogen atom or a hydrogen atom. The method of the present invention includes reacting compound [1] with thionyl chloride to give compound [2] and obtaining the objective compound [7] at a high yield via intermediate [5], and is utilizable for industrial production.